References
Maret-Ouda J, Santoni G, Xie S, Rosengren A, Lagergren J. Proton pump inhibitor and clopidogrel use after percutaneous coronary intervention and risk of major cardiovascular rvents. Cardiovasc Drugs Ther. 2021. https://doi.org/10.1007/s10557-021-07219-6.
Evanchan J, Donnally MR, Binkley P, Mazzaferri E. Recurrence of acute myocardial infarction in patients discharged on clopidogrel and a proton pump inhibitor after stent placement for acute myocardial infarction. Clin Cardiol. 2010;33(3):168–71.
Shi WC, Gao SD, Yang JG et al. Impact of proton pump inhibitors on clinical outcomes in patients after acute myocardial infarction: a propensity score analysis from China Acute Myocardial Infarction (CAMI) registry. J Geriatr Cardiol. 2020;17(11):659–65.
Xie J, Chen Q, He D. Pre-existing Proton Pump Inhibitor Treatment and Short-Term Prognosis of Acute Myocardial Infarction Patients. Front Cardiovasc Med. 2022;9:919716.
Khawaja M, Thakker J, Kherallah R et al. Antacid therapy in coronary artery disease and heart failure: proton pump inhibitors vs. H2 receptor blockers. Cardiovasc Drugs Ther. 2022. https://doi.org/10.1007/s10557-022-07358-4.
Funding
The authors received no financial support for the research, authorship, and/or publication of this article.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interests
The authors report no relationships that could be construed as a conflict of interest.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Wang, XL., Liu, JH. & Mo, DG. The application of proton pump inhibitors in cardiovascular disease needs to be individualized. Cardiovasc Drugs Ther 36, 1247–1248 (2022). https://doi.org/10.1007/s10557-022-07395-z
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10557-022-07395-z